Empowered Funds LLC Has $347,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Empowered Funds LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 6.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,199 shares of the company’s stock after acquiring an additional 322 shares during the period. Empowered Funds LLC’s holdings in Moderna were worth $347,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of MRNA. Intrinsic Value Partners LLC boosted its position in shares of Moderna by 91.1% during the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after acquiring an additional 24,505 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after buying an additional 69,313 shares during the last quarter. Profund Advisors LLC lifted its holdings in shares of Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after acquiring an additional 9,719 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock valued at $25,359,000 after purchasing an additional 15,218 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. TD Cowen lowered their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $84.00.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $43.66 on Tuesday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $16.80 billion, a PE ratio of -7.66 and a beta of 1.69. The stock’s 50 day moving average price is $54.96 and its 200-day moving average price is $93.71. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -9.44 EPS for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. This represents a 13.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 2,930 shares of company stock worth $217,170. Insiders own 15.20% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.